Tag
Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.
The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high ra
A Bayesian network meta-analysis integrating health‑related quality of life and overall survival across first‑line trials in advanced hepatocellular carcinoma shows atezolizumab plus bevacizumab provides the most favorable combined patient‑
In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital dea
Use of systemic anticancer therapy in the last 30 days of life rose from 2015–2020, mainly due to immunotherapy; any SACT was linked to more than twofold higher odds of multiple ED visits, hospitalizations, ICU admission, and in-hospital de
The phase III PACIFIC-2 trial found that giving durvalumab from the start of definitive concurrent chemoradiotherapy failed to improve progression-free or overall survival versus placebo; consolidation durvalumab after chemoradiotherapy rem
The ImmunoSep randomized trial found that biomarker-guided immunotherapy (anakinra for macrophage activation‑like syndrome; interferon‑γ for sepsis‑induced immunoparalysis) improved organ dysfunction by day 9 versus placebo, though 28‑day m
Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th
Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combinati
In a single‑arm phase 2 cohort, pembrolizumab plus lenvatinib produced a 60% objective response rate in 20 patients with pleural mesothelioma progressing after first‑line nivolumab plus ipilimumab, but grade 3–4 toxicities were frequent (70
A Cell study shows head and neck cancers hijack a nerve→lymph node circuit (ATF4→SLIT2→sensory neurons→CGRP) to suppress immunity and cause pain — suggesting nerve-targeting drugs could both ease pain and improve immunotherapy.
A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activ
RNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.
A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric
In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophage
The phase 3 STELLAR-303 trial shows zanzalintinib plus atezolizumab improves overall survival versus regorafenib in previously treated, microsatellite-stable metastatic colorectal cancer, albeit with higher grade ≥3 toxicity.
One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety
Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and s
This case series evaluates relapse rates associated with various maintenance immunotherapies in 54 patients with Susac syndrome, highlighting treatment efficacy and challenges in managing this rare autoimmune disorder.
This article reviews pivotal updates in gastrointestinal oncology from recent trials, emphasizing superior neoadjuvant immunotherapy in mismatch repair–deficient colorectal cancer, promising antibody-drug conjugates, and challenges in novel
